Patents Examined by Sean E Aeder
-
Patent number: 12774349Abstract: Provided are antibodies that target the cellular efflux pump ABCC1. Also provided are pharmaceutical compositions, nucleic acids, recombinant expression vectors, cells, and kits that include or encode such antibodies. Methods of using the antibodies for detecting presence or absence of ABCC1 expression in cells, e.g., tumor cells, Level of ABCC1 expression, and/or inhibiting ABCC1 function are also disclosed. Also provided are methods for treating a subject for a cancer that include administering to the subject an anti-ABCC1 antibody disclosed herein. The subject antibody may be a bispecific antibody. The bispecific antibody may bind to ABCC1 and a tumor associated antigen (TAA).Type: GrantFiled: September 1, 2021Date of Patent: October 27, 2026Assignee: William Robert Arathoon Living Trust Dated August 29, 2016Inventors: William Robert Arathoon, Raffaella Briante, Paul David Ponath, Cindy Tan, Richard Theolis, Qianting Zhai, Pingping Zhang
-
Patent number: 12774331Abstract: An object of the present invention is to provide a bispecific antibody that binds to CD3 or a bispecific antibody fragment thereof. The present invention relates to a bispecific antibody that binds to CD3 or a bispecific antibody fragment thereof, a DNA encoding the bispecific antibody or the bispecific antibody fragment thereof, a vector containing the DNA, a hybridoma and a transformant that produce the bispecific antibody or the bispecific antibody fragment thereof, a method for producing the bispecific antibody or the bispecific antibody fragment thereof, therapeutic and diagnostic agents containing the bispecific antibody or the bispecific antibody fragment thereof, therapeutic and diagnostic methods using the bispecific antibody or the bispecific antibody fragment thereof, and a reagent for detection or measurement containing the bispecific antibody or the bispecific antibody fragment thereof.Type: GrantFiled: February 12, 2021Date of Patent: October 27, 2026Assignee: KYOWA KIRIN CO., LTD.Inventors: Rinpei Niwa, Shinya Ogawa, Mami Wajima, Tsuguo Kubota
-
Patent number: 12774326Abstract: An object of the present invention is to provide an agent for preventing or treating frontotemporal lobar degeneration which does not cause noticeable adverse reactions and exhibits an excellent effect of preventing and treating frontotemporal lobar degeneration caused by different factors. In the present invention, a human monoclonal antibody that specifically binds to human HMGB1, which comprises heavy chain CDR1, heavy chain CDR2, and heavy chain CDR3 each consisting of a specific amino acid sequence and light chain CDR1, light chain CDR2, and light chain CDR3 each consisting of a specific amino acid sequence, can be used as an agent for preventing or treating frontotemporal lobar degeneration.Type: GrantFiled: December 6, 2021Date of Patent: October 27, 2026Assignee: INSTITUTE OF SCIENCE TOKYOInventor: Hitoshi Okazawa
-
Patent number: 12774338Abstract: [Problem] Provided is a multispecific antibody for preventing or treating amyotrophic diseases such as inclusion body myositis by binding to ActRIIA, ActRIIB, and Fn14, and inhibiting an amyotrophic action which occurs via ActRIIA, ActRIIB, and Fn14. [Means for Solution] The present inventors have conducted studies on a multispecific antibody, and provided a multispecific antibody including a polypeptide consisting of the amino acid sequence of SEQ ID NO: 2 and a polypeptide consisting of the amino acid sequence of SEQ ID NO: 4.Type: GrantFiled: January 12, 2022Date of Patent: October 27, 2026Assignee: Astellas Pharma Inc.Inventors: Shinji Soga, Takeshi Shigenaga, Takeshi Tsutsumi
-
Patent number: 12767732Abstract: Provided are a protein complex having a high heterodimer formation rate, a method of preparing the same, a pharmaceutical composition for preventing or treating cancer including the protein complex, and a method or preventing or treating cancer using the same. According to the same, bispecific antibodies or antigen-binding fragments with increased stability, receptors and receptor-binding agonists, antagonists, ligands, cytokines or receptor decoy biconjugates may be easily prepared and used in various fields such as disease prevention or treatment, and disease diagnosis.Type: GrantFiled: May 28, 2021Date of Patent: October 20, 2026Assignee: MUSTBIO CO., LTD.Inventors: Sung Youb Jung, Young Jin Park, Hyo Joo Bang, Maeng Sup Kim
-
Patent number: 12758582Abstract: A suite of novel anti-CD33 antibodies is described. The provided antibodies are pan-binders, binding the C2-set Ig-like domain in the presence or absence of the V-set Ig-like domain of CD33; are C2-set specific binders, binding the C2-set Ig-like domain only in the absence of the V-set Ig-like domain of CD33; or are V-set binders, binding the V-set Ig-like domain of CD33. The antibodies provide novel therapeutic and diagnostic tools against CD33-related disorders, such as acute myeloid leukemia (AML).Type: GrantFiled: March 31, 2021Date of Patent: October 13, 2026Assignee: Fred Hutchinson Cancer CenterInventors: Roland B. Walter, George S. Laszlo
-
Patent number: 12760117Abstract: The present disclosure describes compositions and methods for treating solid tumors expressing mesothelin (MSLN) using chimeric antigen receptor (CAR) T cell therapy. The compositions comprise CARs with an extracellular domain that specifically binds MSLN. The extracellular domain comprises a single variable domain (VHH) antibody that targets MSLN. Polynucleotides encoding the anti-MSLN CAR constructs are provided. Pharmaceutical compositions comprising CAR T cells expressing the anti-MSLN CARs are also described. The CAR T cells demonstrate cytotoxicity against MSLN-expressing tumor cells in vitro and anti-tumor activity in vivo. Methods are provided for generating the CAR T cells by transfecting T cells with lentiviral or retroviral vectors carrying anti-MSLN CAR encoding sequences. The anti-MSLN CAR T cell therapy described herein provides an effective approach for treating solid tumors expressing MSLN, such as mesothelioma, ovarian cancer, pancreatic cancer, and lung cancer.Type: GrantFiled: December 14, 2023Date of Patent: October 13, 2026Assignees: Innovative Cellular Therapeutics Holdings, Ltd., Innovative Cellular Therapeutics, Inc.Inventors: Xiaogang Shen, Wensheng Wang, Xudong Tang, Chengfei Pu, Zhao Wu, Lei Xiao
-
Patent number: 12760124Abstract: The disclosure provides trispecific and/or trivalent binding proteins comprising four polypeptide chains that form three antigen binding sites that specifically bind one or more target proteins, wherein a first pair of polypeptides forming the binding protein possess dual variable domains having a cross-over orientation and wherein a second pair of polypeptides forming the binding protein possess a single variable domain. The disclosure also provides methods for making trispecific and/or trivalent binding proteins and uses of such binding proteins.Type: GrantFiled: February 5, 2024Date of Patent: October 13, 2026Assignee: SanofiInventors: Zhi-Yong Yang, Gary J. Nabel, Lan Wu, Edward Seung, Ronnie Wei, Jochen Beninga, Ercole Rao, Wulf Dirk Leuschner, Christian Beil, Christian Lange, Carsten Corvey
-
Patent number: 12753232Abstract: The present disclosure provides a fusion protein including an anti-CD3 single domain antibody, an exosomal protein CD63 and an RNA binding protein. The fusion protein of the present disclosure achieves the effect of treating cancer, immunoregulation and activating immune cells through various efficacy experiments.Type: GrantFiled: December 26, 2025Date of Patent: October 6, 2026Assignee: CHINA MEDICAL UNIVERSITY HOSPITALInventors: Der-Yang Cho, Shao-Chih Chiu, Shi-Wei Huang, Chih-Ming Pan, Mei-Chih Chen, Yu-Chuan Lin, Yeh Chen, Yi-Wen Chen, Chung-Chun Wu, Kai-Wen Kan
-
Patent number: 12752007Abstract: An inducible chimeric antigen receptor and its application relate to the field of immune therapy. The inducible antigen receptor includes a single-chain variable fragment (scFv) antibody against human CSF1R, a truncated hIgG1 hinge region SH, a T cell co-stimulatory signaling molecule, and a T cell cytoplasmic signaling domain. Transcription of the chimeric antigen receptor is regulated by an inducible expression element tet operator. The induce chimeric antigen receptor molecules can be used to modify T lymphocytes, eliminating the cytokine storm problem of CAR-T cells in the treatment of Alzheimer's disease (AD), and achieving target treatment of AD.Type: GrantFiled: March 6, 2023Date of Patent: October 6, 2026Assignee: Beijing Tiantan Hospital, Capital Medical UniversityInventors: Jun Xu, Yanli Wang, Jiwei Jiang, Zhongli Du, Zhenlan Du
-
Patent number: 12746272Abstract: The present invention relates to a method of treating, preventing or delaying the progression of cancer and/or tumour in a subject comprising administering to the subject a treatment regimen comprising an effective amount of modified immunoresponsive cells expressing or presenting a heterologous T-cell receptor (TCR) having the property of binding to MAGE A4.Type: GrantFiled: May 13, 2021Date of Patent: September 29, 2026Inventor: Dennis Robert Williams
-
Patent number: 12742780Abstract: Provided are methods and related kits for detection of early stage ovarian cancer, and determination of being at risk for ovarian cancer.Type: GrantFiled: April 10, 2023Date of Patent: September 22, 2026Assignee: Board of Regents, The University of Texas SystemInventors: Johannes Fahrmann, Samir Hanash
-
Patent number: 12735485Abstract: The invention relates to novel bispecific antigen binding molecules, comprising at least two antigen binding domains capable of specific binding to OX40 and a particular antigen binding domain capable of specific binding to Fibroblast Activation Protein (FAP), and to methods of producing these molecules and to methods of using the same.Type: GrantFiled: August 29, 2023Date of Patent: September 15, 2026Assignee: Hoffmann-La Roche Inc.Inventors: Maria Amann, Juergen Peter Bachl, Alexander Bujotzek, Carina Cantrill, Harald Duerr, Janine Faigle, Sabine Imhof-Jung, Christian Klein, Thomas Kraft, Estelle Marrer-Berger, Ekkehard Moessner, Laurene Pousse, Petra Rueger, Johannes Sam, Roland Staack, Dietrich Tuerck, Pablo Umaňa, Joerg Zielonka
-
Patent number: 12723099Abstract: Disclosed herein are isolated polypeptides or polypeptide complexes that comprise a tumor-associated calcium signal transducer 2 (TROP2) binding domain that has been optimized for binding and kinetic properties. In some embodiments, the isolated polypeptides or polypeptide complexes further comprise a CD3 binding domain.Type: GrantFiled: May 8, 2023Date of Patent: September 1, 2026Assignee: JANUX THERAPEUTICS, INC.Inventors: David Campbell, Thomas R. Diraimondo
-
Patent number: 12723088Abstract: The invention relates to antigen-binding molecules that specifically bind to MHC Class I DLA-12 antigen. In one embodiment, the antigen-binding molecule is an antibody that specifically binds to canine MHC Class I DLA-12 antigen. Chimeric molecules of the antibody conjugated to another heterologous moiety are also provided. In one embodiment, the heterologous moiety is monomethyl auristatin E (MMAE). A method of inhibiting cancer using the antibody or the chimeric molecule thereof is also provided. In another embodiment, the antibody-MMAE conjugate suppresses tumour development in a murine model of B cell lymphoma.Type: GrantFiled: January 28, 2022Date of Patent: September 1, 2026Assignee: Agency for Science, Technology and ResearchInventors: Chui Ping Angela Chin, Boon Hwa Andre Choo, Wey Jia Fong, Mei Yee Vanessa Ding
-
Patent number: 12710425Abstract: The present disclosure relates to a composition capable of diagnosing cancer, specifically pancreatic cancer or the like, a diagnostic kit comprising the same, and a method of providing information for diagnosis using the composition. Also, the present disclosure relates to a pharmaceutical composition capable of preventing or treating pancreatic cancer.Type: GrantFiled: May 21, 2020Date of Patent: August 18, 2026Assignee: ACURASYSBIO CO., LTD.Inventors: Hyung Keun Lee, Dong Ki Lee, Sung Ill Jang, So Young Kim, A Reum Yeo, Jong Kyoung Kim, Eun-Ju Chang
-
Patent number: 12703755Abstract: Provided are an antibody targeting BCMA, a bispecific antibody targeting BCMA and CD3, and applications thereof. The antibody targeting BCMA comprises two heavy chain variable regions, the heavy chain variable regions comprising HCDR1, HCDR2, and HCDR3 as shown in the amino acid sequences of SEQ ID NO: 22, SEQ ID NO: 33 and SEQ ID NO: 42, or HCDR1, HCDR2, and HCDR3 as shown in the amino acid sequences of SEQ ID NO: 26, SEQ ID NO: 37 and SEQ ID NO: 41. The antibody effectively targets human BCMA and binds to cynomolgus BCMA; the bispecific antibody effectively targets both human BCMA and human CD3, and can bind to cynomolgus BCMA and cynomolgus CD3.Type: GrantFiled: September 29, 2020Date of Patent: August 11, 2026Assignee: HARBOUR BIOMED (SUZHOU) CO., LTD.Inventors: Lei Shi, Xuekun Zhang, Yun He, Jianxun Zhao, Wei Zhou, Fei Chen, Xiangyang Tan, Yiping Rong
-
Patent number: 12698330Abstract: The present disclosure provides a fusion protein including an anti-CD3 single domain antibody, an exosomal protein CD63 and an RNA binding protein. The fusion protein of the present disclosure achieves the effect of treating cancer, immunoregulation and activating immune cells through various efficacy experiments.Type: GrantFiled: December 26, 2025Date of Patent: August 4, 2026Assignee: CHINA MEDICAL UNIVERSITY HOSPITALInventors: Der-Yang Cho, Shao-Chih Chiu, Shi-Wei Huang, Chih-Ming Pan, Mei-Chih Chen, Yu-Chuan Lin, Yeh Chen, Yi-Wen Chen, Chung-Chun Wu, Kai-Wen Kan
-
Patent number: 12692321Abstract: A humanized antibody or antigen binding fragment that binds to the poliovirus receptor (PVR) can be utilized in the preparation of antibody drug conjugates (ADCs) to target nucleic acids, peptides and proteins, drugs and radiopharmaceuticals to cancer cells. These antibodies or antigen binding fragments can also be used for checkpoint blockade. The humanized antibody or antigen binding fragment of this invention can also modulate the PVR-DNAM-1 axis in order to upregulate DNAM 1 (CD226) expression on T cells or NK cells. The antibody or antigen binding fragment that bind to PVR can also be incorporated in CAR-T cells or CAR-NK cells. Bispecific antibodies can also be produced by incorporating the anti-CD155 antibodies or antigen binding fragments to engage T cells or NK cells to fight cancers that express CD155.Type: GrantFiled: August 20, 2021Date of Patent: July 28, 2026Assignee: TASRIF PHARMACEUTICAL, LLCInventors: Aftab S. Karim, Robert Holgate, Arron Hearn
-
Patent number: 12686708Abstract: To allow control over injected genetically engineered cells, it is helpful that the genetically engineered cells express a marker that can be used to detect such cells among a pool of unmodified cells. Some embodiments relate to a marked protein comprising a TCR constant domain and an exogenous amino acid variation that comprises a sequence that is detectable and identifiable within the TCR constant domain. Other embodiments relate to an antibody epitope that is attached to a TCR chain. Both the marked proteins and the antibody epitopes can be used to track genetically engineered cells.Type: GrantFiled: December 21, 2021Date of Patent: July 21, 2026Assignee: NEOGENE THERAPEUTICS B.V.Inventors: Carsten Linnemann, Thomas Kuilman, Gavin M. Bendle, Jeroen W.J. van Heijst, Xiangjun Kong, Loek Josephus Eggermont